Answers are grounded in this paper and cite their sources.
Friedreich’s ataxia (FA) is a progressive neurodegenerative disorder frequently associated with hypertrophic cardiomyopathy and heart failure, a major cause of mortality. FA results from frataxin deficiency, leading to mitochondrial dysfunction, impaired iron–sulfur cluster biogenesis, and oxidative stress. We examined the effect of two clinically relevant Nrf2 activators, dimethyl fumarate (DMF) and omaveloxolone (OMAV), on their ability to restore cardiac function in an inducible and reversible frataxin-knockdown (FXNKD) mouse model of FA. FXNKD mice developed a heart failure with preserved ejection fraction–like phenotype, characterized by left ventricular wall thickening, impaired diastolic relaxation, and reduced stroke volume, with more severe remodeling observed in males. Both treatments activated canonical Nrf2 signaling, confirming target engagement. DMF partially improved cardiac function in males, increasing stroke volume, enhancing metabolic flexibility, and restoring mitochondrial enzyme activity; however, diastolic dysfunction persisted. OMAV treatment was associated with female-specific electrophysiological abnormalities, including increased arrhythmic burden and reduced J-wave amplitude, with persistent fibrotic remodeling. Both treatments attenuated region-specific cardiomyocyte atrophy in FXNKD males and females. These findings suggest that Nrf2 activation alone is insufficient to reverse FA-associated cardiomyopathy and reveal sex-dependent therapeutic responses. Further investigation of complementary treatment strategies may help address persistent cardiac dysfunction and remodeling in FA.
No takes yet. Share an insight, caveat, or question.
Figueroa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: